| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522191 | AYTU | Modified release formulations containing drug—ion exchange resin complexes |
Jun, 2027
(3 years from now) | |
| US8062667 | AYTU | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
Karbinal Er is owned by Aytu.
Karbinal Er contains Carbinoxamine Maleate.
Karbinal Er has a total of 2 drug patents out of which 0 drug patents have expired.
Karbinal Er was authorised for market use on 28 March, 2013.
Karbinal Er is available in suspension, extended release;oral dosage forms.
The generics of Karbinal Er are possible to be released after 29 March, 2029.
Drugs and Companies using CARBINOXAMINE MALEATE ingredient
Market Authorisation Date: 28 March, 2013
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
KARBINAL ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic